AI Image
Prostate cancer genomic test could spare men from extra hormone therapy
Fox News • • health
Key Points:
- Researchers at University College London studied the Decipher molecular test to identify which men with high-risk prostate cancer would benefit from intensive hormone therapy, potentially avoiding unnecessary side effects.
- The study analyzed data from over 27,000 patients and 401 men from the STAMPEDE trial, finding that higher Decipher scores predicted worse outcomes and a greater need for additional treatment.
- Results suggest genomic testing with Decipher could personalize prostate cancer treatment, helping to determine who requires more aggressive therapy and who might safely avoid it.
- Experts emphasize the importance of further validation before routine clinical use but highlight the test's potential to improve patient quality of life by tailoring treatment intensity.
- Prostate cancer remains a major health concern, being the second-leading cause of cancer death in men, with about one in eight American men diagnosed during their lifetime.
